FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

CADILAHC

463.35
+12.55 (2.78%)
Updated 03:29 03/12 IST

CADILAHC Buy or Sell - FrontPage Forums

3 Users have submitted 5 trade ideas of Rs. 2,163,370 for CADILAHC
Disclaimer
100% Bullish
0% Bearish

CADILAHC Buy or Sell - Brokerage Reports

No. of reports in last year
7
No. of analysts
5
Average Consensus Forecast
348.57
Consensus Potential
-34.12%
See CADILAHC Share Price Targets >>

CADILAHC Ratings

Long term CADILAHC rating by FrontPage users
4.3/5 (7 Ratings)
Find answers to all your questions on live CADILAHC message board: Is CADILAHC buy or sell? Should I buy CADILAHC shares? Why are CADILAHC shares falling? Should I invest in CADILAHC stock?

  1. Home
  2. CADILAHC Forum

CADILAHC Share Price Discussion

D
Reputation: 120,837 • Yesterday 10:15 AM
Dcj196 in NIFTY-50
#NIFTY50 #CADILAHC ....another star trade after...

#NIFTY50 #CADILAHC ....our star trade maruti already rocking...cadila..any time can spike...
Like
Reply

GOLD MEGA FEB CAN BE BOUGHT AT 49395 FOR THE TARGET 49495... TRADERS NOTE...


Like
Reply

Type
Sell
Instrument
NATURALGAS 28DEC20 FUT
Entry Price
₹199.6
Price@Trade
₹199.6
Target Price
₹198
Stop Price
₹200.3
Valid Till
Dec 3, 2020 11:20 AM
Margin
₹43,118.75 approx for 1250 Qty
Status
Active
Like
Reply
S
Reputation: 5,297 • Yesterday 10:09 AM

Type
Buy
Instrument
NATURALGAS 28DEC20 FUT
Entry Price
₹199.5
Price@Trade
₹199.6
Target Price
₹210
Stop Price
₹198.7
Valid Till
Dec 28, 2020 11:20 AM
Margin
₹43,117.19 approx for 1250 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 10:10 AM

Update
Trade Entered
Entry Price
₹199.5

Type
Sell
Instrument
CRUDEOIL 18DEC20 FUT
Entry Price
₹3,332
Price@Trade
₹3,332
Target Price
₹3,300
Stop Price
₹3,337
Valid Till
Dec 3, 2020 11:20 AM
Margin
₹680,130 approx for 200 Qty
Status
Active
Like
Reply
B
Reputation: 9,559 • Yesterday 10:03 AM

Type
Buy
Instrument
ZINC 31DEC20 FUT
Entry Price
₹216
Price@Trade
₹216.1
Target Price
₹225
Stop Price
₹208
Valid Till
Dec 31, 2020 11:20 AM
Margin
₹118,500 approx for 5000 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 10:07 AM

Update
Trade Entered
Entry Price
₹216
N
Reputation: 8,301 • Yesterday 9:58 AM
Tata Nexon EV crosses 2,000 sales mark
In over 10 months, since launch, the sales of the Nexon EV reached 2,200 units as of last month indicating the rapid demand for electric vehicles the personal car segment, the auto major said in a statement.
Moneycontrol
Like
Reply
N
Reputation: 8,301 • Yesterday 9:58 AM
Bank of India to acquire 49% stake each in BOI AXA Investment Managers, BOI AXA Trustee Services
Following the transaction, both the entities -- BOI AXA Investment Managers Pvt Ltd (BAIM) and BOI AXA Trustee Services Pvt Ltd (BATS) -- will become Bank of India''s fully owned subsidiaries.
Moneycontrol
Like
Reply
N
Reputation: 8,301 • Yesterday 9:58 AM
Roshni Nadar tops Kotak Wealth and Hurun India's list of richest women
Biocon Chairperson Kiran Mazumdar-Shaw is the second-richest woman on the list, with a net worth of 36,600 crore
Moneycontrol
Like
Reply

Type
Buy
Instrument
GOLD 05FEB21 FUT
Entry Price
₹49,470  ₹49,371
Price@Trade
₹49,367
Target Price
₹50,470
Stop Price
₹48,470
Valid Till
Feb 5, 2021 11:20 AM
Margin
₹710,800 approx for 200 Qty
Status
Active
Like
Reply (2)
See all replies
shailesh jain @shaileshjain
Yesterday 10:01 AM

Update
Entry Price Modified
Price @ Update
₹49,371
Original Entry Price
₹49,470
New Entry Price
₹49,371
TrackerBot @trackerbot
Yesterday 10:01 AM

Update
Trade Entered
Entry Price
₹49,371

Type
Sell
Instrument
NATURALGAS 28DEC20 FUT
Entry Price
₹200
Price@Trade
₹200.2
Target Price
₹198
Stop Price
₹202
Valid Till
Dec 3, 2020 11:20 AM
Margin
₹43,125 approx for 1250 Qty
Status
Active
CMP 200.10 .
Like
Reply (3)
See all replies
TrackerBot @trackerbot
Yesterday 9:58 AM

Update
Trade Entered
Entry Price
₹200
Kerala Mcx Trader @keralamcxtrader
Yesterday 10:05 AM

Ok
Kerala Mcx Trader @keralamcxtrader
Yesterday 10:05 AM

Cmp 199.50

Type
Buy
Instrument
GOLDM 05JAN21 FUT
Entry Price
₹49,362
Price@Trade
₹49,362
Target Price
₹100,000
Stop Price
₹0
Valid Till
Jan 5, 2021 11:20 AM
Margin
₹355,502.5 approx for 1000 Qty
Status
Active
Like
Reply
N
Reputation: 8,301 • Yesterday 9:53 AM
Titan shares hit 52-week high; wedding season, pent-up demand likely to boost stock further
Brokerages and analysts point out that strong wedding season, pent-up demand and stable gold prices are boosting demand for jewelry which is expected to augur well for Titan.
Moneycontrol
Like
Reply
N
Reputation: 8,301 • Yesterday 9:53 AM
Bank Of India shares rise 4% on acquiring controlling stake in subsidiaries
The share touched its 52-week high Rs 79.80 and 52-week low Rs 30.45 on 28 November, 2019 and 13 March, 2020, respectively.
Moneycontrol
Like
Reply
D
Reputation: 120,837 • Yesterday 9:49 AM
Dcj196 in TATAPOWER
Trade entered: Buy TATAPOWER DEC20 60 CE @6.35 ...
Like
Reply
A
Reputation: 754 • Yesterday 9:49 AM

Type
Buy
Instrument
NATURALGAS 25JAN21 FUT
Entry Price
₹201  ₹201.3
Price@Trade
₹201.2
Target Price
₹203
Stop Price
₹199.9
Valid Till
Dec 3, 2020 11:20 AM
Margin
₹39,395.31 approx for 1250 Qty
Status
Active
Like
Reply (2)
See all replies
Asmik @asmik
Yesterday 9:49 AM

Update
Entry Price Modified
Price @ Update
₹201.3
Original Entry Price
₹201
New Entry Price
₹201.3
TrackerBot @trackerbot
Yesterday 9:50 AM

Update
Trade Entered
Entry Price
₹201.3

Type
Sell
Instrument
CRUDEOIL 18DEC20 FUT
Entry Price
₹3,330
Price@Trade
₹3,330
Target Price
₹3,320
Stop Price
₹3,336
Valid Till
Dec 3, 2020 11:20 AM
Margin
₹680,127.5 approx for 200 Qty
Status
Stoploss Hit
Exit Price
₹3,336
Net P&L
-₹1,200 (-0.18%)
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 9:53 AM

Update
Stoploss Hit
Exit Price
₹3,336
N
Reputation: 8,301 • Yesterday 9:46 AM
Firms have accelerated the adoption of automation, digital business models: Infosys-HFS Research study
Investments in the cloud, cybersecurity, and modernizing core IT apps and infrastructure are at the top of the priority heap, top executives said.
The Economic Times
Like
Reply

NATURAL GAS INVENTORIES FORECAST -17B VS PREVIOUS -18B IS SLIGHTLY POSITIVE FOR NATURAL GAS .

#CRUDEOIL
1
Reply

Type
Buy
Instrument
NATURALGAS 28DEC20 FUT
Entry Price
₹200
Price@Trade
₹200.1
Target Price
₹202
Stop Price
₹198
Valid Till
Dec 28, 2020 11:20 AM
Margin
₹43,126.56 approx for 1250 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 9:41 AM

Update
Trade Entered
Entry Price
₹200
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • CADILAHC - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization35,491.84
    Enterprise Value38,320.54
    Price to Earnings35.57
    Price to Book Value3.96
    Return on Capital Employed0.15
    Return on Equity0.14
    Face Value1
    Dividend Yield0.01
  • CADILAHC - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    7-Nov-20Geojit Financial ServicesBuy511
    3-Nov-20Prabhudas LilladherSell357
    8-May-20Prabhudas LilladherSell263
    7-Apr-20Karvy Stock BrokingBuy362
    7-Feb-20Karvy Stock BrokingBuy316
    CADILAHC Brokerage Price Target
  • CADILAHC Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Dec 3450.8463.8450.8462.95
    Dec 2453455.85445.1450.8
    Dec 1459.1459.4442.3453.65
    Nov 27439459432.2450.1
    Nov 26422426.8418.1422.3
  • CADILAHC Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹433.41
    30 Day Moving Average₹429.76
    50 Day Moving Average₹422.07
    100 Day Moving Average₹400.36
    200 Day Moving Average₹357.61
  • CADILAHC - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue5,8093,230.70.8
    Operating Profit1,646321.14.13
    Profit Before Tax1,497642.21.33
    Net Income1,090661.90.65
  • CADILAHC - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds8,9567,7450.16
    Total Liabilities4,5364,4840.01
    Total Assets13,49212,2300.1
  • CADILAHC - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity2891,291.9-0.78
    Cash from Investing Activity26-2,904.5-1.01
    Cash from Financing Activity-1481,365.6-1.11
    Net Cash Flow167-247-1.68
  • CADILAHC - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.090.06
    Return on Equity0.140.1
    Return on Capital Employed0.150.07
  • CADILAHC - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.1
    3 Year CAGR Growth in Operating Profit0.07
    3 Year CAGR Growth in EBIDTA0.08
    3 Year CAGR Growth in Net Income-0.14
    3 Yr CAGR Growth - Diluted EPS-0.83
  • CADILAHC - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.65
    5 Year CAGR Growth in Operating Profit1.33
    5 Year CAGR Growth in EBIDTA1.44
    5 Year CAGR Growth in Net Income1.19
    3 Yr CAGR Growth - Diluted EPS-0.56
  • CADILAHC - Recent News

    keyboard_arrow_down
    NewsBot
    Dec 2 10:21 AM
    PM Modi to attend FICCI's virtual 93rd annual general meeting
    The Economic Times
    NewsBot
    Nov 28 11:53 AM
    PM Narendra Modi reviews vaccine development at Zydus Cadila facility in Gujarat
    Moneycontrol
    NewsBot
    Nov 28 11:53 AM
    Cadila Healthcare shares up 3% on plans to launch COVID-19 vaccine by March 2021
    Moneycontrol
    NewsBot
    Nov 27 5:31 AM
    Cadila Healthcare advances 5% as drugmaker may introduce Covid vaccine by March
    The Economic Times
    NewsBot
    Nov 13 10:13 AM
    COVID-19 Vaccine Tracker: Here's a status update on leading coronavirus vaccines that are ahead of the pack
    Moneycontrol
    NewsBot
    Nov 12 5:33 AM
    Cadila Healthcare shares up 4% on completion of phase-II trial of COVID vaccine
    Moneycontrol
    NewsBot
    Nov 10 3:06 AM
    Gautam Shah’s 3 firecracker stock ideas for Samvat 2077
    The Economic Times
    NewsBot
    Nov 7 12:33 PM
    Accumulate Cadila Healthcare; target of Rs 497: Dolat Capital Market
    Moneycontrol
    NewsBot
    Nov 7 7:23 AM
    Buy Cadila Healthcare; target of Rs 555: ICICI Direct
    Moneycontrol
    NewsBot
    Nov 6 10:28 AM
    Sell Cadila Healthcare; target of Rs 357: Prabhudas Lilladher
    Moneycontrol
  • CADILAHC - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • CADILAHC - More Information

    keyboard_arrow_down

    Cadila HealthcareLtd:
    Cadila Healthcare Limited is associated with researching, producing, developing, marketing and distributing pharmaceutical products in India and several other countries like Spain, South Africa, France as well as Latin American countries. It offers a wide range of products, including wellness products, active pharmaceutical ingredients, human dosage formulations, vaccines, animal healthcare products, and biosimilars.
    Apart from this, the company offers several other products in various medical aspects of pain-management, gastrointestinal therapy, gynaecology, dermatology, respiratory issues, etc. Among some of its famous products are, Glucon-D (glucose power, EverYuth in their skincare products range, Sugar-Free and Nycil (prickly heat talc).
    Additionally, Cadila has ongoing development of 21 biosimilars along with six different novel products. It also has drugs in multiple aspects for treatment of autoimmune diseases, cancer, diseases concerned with ophthalmology, hepatology, nephrology, rheumatology and several infectious diseases. It also associates itself with retail pharmacy, labour supply along with administration activities. Cadila is an Ahmedabad based company in India and was incorporated back in 1952.
    About Company Information:
    In 1996, Cadila Healthcare Ltd launched Falcigo through a strategic alliance agreement with a China-based company named Gulin Pharma. In MAY, 2000 Cadila had a helping hand for strengthening its southern market by acquiring Recon Ltd. In the following year, the company acquired German Remedies. This newly acquired company was the top M&A company in the pharmaceutical sector in India.
    In the same year, 2001, Cadila entered into an alliance with Oncova with the aim of running research together in the aspect of Oncogenomics. The next year, in 2002, the company went on to acquire Banyan Chemicals. In the following year, in 2003, Zydus Pathline, German Remedies, Zoom Properties and Recon Healthcare, all of them merged with Cadila Healthcare Ltd.
    In 2005, Cadila Healthcare Ltd. entered into a strategic agreement with Mallinckrodt Pharmaceuticals Generics. This was a strategic alliance for marketing products launched by Mallinckrodt through one of their business units, under a single joint label.In 2005 itself, the company wished to cater to international needs by manufacturing active pharmaceutical ingredients and cytotoxic drugs along with injectables, for this purpose it signed a fifty-fifty joint agreement with Mayne Pharma, an Australia based company.
    During 2005-2006 the company signed an agreement with Bharat Serums and Vaccines Ltd. These two companies came together to form Zydus BSV Pharma Private Limited for developing, manufacturing and marketing proprietary Novel Drug Delivery System that would sell anti-cancer goods in international markets.
    During 2007-2008, Cadila launched two new divisions, namely, Fortiza and Corza, while focusing on restructuring their existing Alidac division. In February of 2008, in the aspect of research in drug discovery and their development, Cadila went into a 3-year contract with a Swedish company Karo Bio.
    On the 28th of January in 2011, Bayer Healthcare had signed an agreement with Cadila for setting up Bayer Zydus Pharma which will be responsible for selling pharmaceutical products in India. Each of these two companies entering the alliance were to hold 50 of shares each and have equal representation on the board, Bayer Zydus was headquartered in Mumbai.
    On 25th of July, 2013, Cadila along with a non-profit organization based in Seattle, named IDRI, declared that these two organizations would collaborate for clinical development of IDRI’s VL vaccine for attacking parasites. It was also agreed upon that Cadila would also be responsible for producing this product.
    On the 31st of December, 2015, the company informed that the USFDA sent a letter of warning for the company’s Ahmedabad active pharmaceutical ingredients facility and its Moraiya formulation. In February of 2016, the company informed that it was permitted by the USFDA for marketing Doxycycline Capsules USP, 100 mg, 50 mg, and 75 mg.
    On the 28th of March, 2016, Cadila announced that its subsidiary company Zydus was all set to acquire Actibile from a company named Albert David Ltd. This brand of the drug is for gastroenterology aspect and also used for treating stones in the gallbladder.
    How Cadila HealthcareLtd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cadila Healthcare Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cadila HealthcareLtd, Competitors and Sector Peers:
    Aarey Drugs & Pharmaceuticals Ltd. AARDRU
    Aarti Drugs Ltd. AARTDR
    Aayush Food & Herbs Ltd. AAYFOO
    Abbott India Ltd. ABBIND
    ABL Bio-Technologies Ltd. ABLBIO
    Addlife Pharma Ltd. ADDPHA
    Bacil Pharma Ltd. BACPHA
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Brooks Laboratories Ltd. BROLAB
    Cipla Ltd. CIPLTD
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    Dujohn Laboratories Ltd. DUJLAB
    Earum Pharmaceuticals Ltd.
    Elder Health Care Ltd. ELDHEA
    Elder Pharmaceuticals Ltd. ELDPHA
    Elegant Pharmaceuticals Ltd. ELEPHA
    Gennex Laboratories Ltd. GENLAB
    Genomics Biotech Ltd. GENBIO
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    JK Pharmachem Ltd. JKPHAL
    Jubilant Life Sciences Ltd. JUBILO
    Jupiter Bioscience Ltd. JUPIBI
    Lupin Ltd. LUPLTD
    Lyka Labs Ltd. LYKLAB
    Novartis India Ltd. NOVAIN
    Ortin Laboratories Ltd. ORTLAB
    Piramal Enterprises Ltd. NICPIR
    Piramal Phytocare Ltd. PIRLIF
    Ranbaxy Laboratories Ltd. RANLAB
    Sanjivani paranteral Ltd. SANPAR
    Sanofi India Ltd. AVEPHA
    Sarvodaya Labs Ltd. SARLAB
    Sun Pharmaceutical Industries Ltd. SUN28
    TTK Healthcare Ltd. TTKHEA
    Venmax Drugs & Pharmaceuticals Ltd. YENDRU
    Venus Remedies Ltd. VENREM
    Zenith Healthcare Ltd. ZENHEA
    Zenlabs Ethica Ltd. SHRLAK
    Zenotech Laboratories Ltd. ZENLAB
    Zim Laboratories Ltd. ZIMLAB
    Zora Pharma Ltd.[Amalgamated] ZORPHA
    Zota Healthcare Ltd. ZOTHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020